Fotemustine
Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma.
≈ 2 min read
Fotemustine. encyclopegia.org, snapshot enwiki-001336668257. /a/fotemustine
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA.[1] A study[2] has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).
External links
edit edit source- ^ Menaa, Farid (2013). "Latest Approved Therapies for Metastatic Melanoma: What Comes Next?". Journal of Skin Cancer. 2013: 1–10. doi:10.1155/2013/735282. PMC 3595667. PMID 23533766. Wikipedia revision 1336668257, retrieved 2026-11-19
- ^ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study". Journal of Clinical Oncology. 22 (6): 1118–25. doi:10.1200/JCO.2004.04.165. PMID 15020614. Wikipedia revision 1336668257, retrieved 2026-11-19
(M phase)
inhibitor
(S phase)
(CCNS)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Text derived from https://en.wikipedia.org/w/index.php?oldid=1336668257 under CC BY-SA 4.0; modifications have been made.